Komo Expands Across Canada with Whole Foods Market

Komo Expands Across Canada with Whole Foods Market

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) (the "Company", "Komo"), a premium plant‐based food company, reports planned expansion across Canada with Whole Foods Market.

Komo Plant Based Foods Inc., a fast growing plant-based food products manufacturer, announces today that it will be expanding its presence in Canada through additional distribution at Whole Foods Markets. Komo's line of frozen meals and meal helpers will now be available in all 14 Whole Foods Market locations in Canada, with the newly expanded listings to be on shelves by May of 2023.

Whole Foods West will be expanding their line of Komo frozen foods from 3 SKUs to 5 SKUs in western Canada and Whole Foods Ontario will be carrying all 5 SKUs, including Komo's 2 serve Lasagna, 2 serve Shepherds Pie, 2 serve Mac & Greens, as well as Komo's line of Meal Helpers: BBQ Mushroom Lentil Taco Filling and Walnut Mushroom Bolognese.

"We're thrilled that Whole Foods Market is adding more Komo products to their selection and continues to support Komo's efforts to bring convenience and high quality plant-based meals to our shared end-consumer," says William White, CEO of Komo. "Our goal has always been to make plant-based eating accessible to everyone, and this expansion into Whole Foods nationally takes us one step closer to achieving that goal"

About Komo

Komo Plant Based Foods is a premium plant-based food company that develops, manufactures and sells a variety of plant-based frozen meals that are always hearty, satisfying and made with wholesome ingredients. Komo's mission is to help make plant-based meals a staple on every dinner table by sharing the company's love for feel-good food that connects the people to the planet. The company believes plant-based eating is the future and that "Change can start with a single bite." The company's experienced plant-based innovation and development team recreates vegan versions of traditionally cheesy and meaty classics, with 100 per cent plants. Komo's 9 products are sold direct-to-consumer through the company's e-commerce website, and a distribution network of on-line and brick and mortar grocery, convenience and natural retailer channels. The company launched in 2021 with the company's flagship products: plant-based lasagna, shepherd's pie and chickenless pot pie, and Komo Plant-Based Meal Helpers -- versatile meal starters to allow the creation of many dishes at home. Komo's newest product is Mac & Greens. All of the company's products are 100-per-cent plant-based, made with wholesome ingredients, free from preservatives and frozen for freshness. Freezing products is a natural and effective way of keeping food products for longer without having to use any preservatives. Komo's meals have an 18-month frozen shelf life. Komo's products are now available in over 840 retail locations across Canada.

Learn more at: www.komocomfortfoods.com and follow on Instagram: @komocomfortfoods For further information, please contact:

William White,
President & CEO,
Komo Plant Based Foods Inc.

will@komoeats.com

+1 (236) 8000‐YUM / (236) 800‐0986

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward‐Looking Statements

Certain statements contained in this press release constitute forward‐looking information.These statements relate to future events or Komo's future performance. The use of any of thewords and similar expressions and statements relating to matters that are not historical factsare intended to identify forward‐looking information and are based on Komo management'scurrent belief or assumptions as to the outcome and timing of such future events. Actual futureresults may differ materially. In particular, Komo's ability to retain key personnel, its projectedrevenues, its projected expenses, its ability to raise capital, and its expectation as to thecontinued increase in the number of retailers and consumers of its products constitute forward‐looking information. Actual results and developments may differ materially from thosecontemplated by forward‐looking information. Readers are cautioned not to place unduereliance on forward‐looking information. The statements made in this press release are madeas of the date hereof. Komo disclaims any intention or obligation to publicly update or reviseany forward‐looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/154231

News Provided by Newsfile via QuoteMedia

YUM:CC
The Conversation (0)
Komo Expands Frozen Meal Line to Fortinos Stores in Toronto

Komo Expands Frozen Meal Line to Fortinos Stores in Toronto

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the "Company", "Komo"), Komo Plant Based Foods Inc. Expands Frozen Meal Line to All 9 SKUs in Fortinos Stores in Toronto.

Komo Plant Based Foods Inc., a premium, fast-growing plant-based food products manufacturer, is thrilled to announce the expansion of their frozen meal line to all 9 SKUs in Fortinos stores across the Greater Toronto Area (GTA). The partnership will make Komo's delicious and nutritious plant-based meals more accessible to families in Toronto, helping to make healthy meal planning more convenient and affordable.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOD) (FSE: 9HB) ("Komo"), a premium plant-based food company, is pleased to announce it achieved record revenues for its second financial quarter ended January 31, 2023. Komo generated revenues of $466,197 in the quarter, which is a 160% increase from the first quarter revenues of $179,467. The increase is attributed to Komo's recent growth across Canada with its retail distribution through Loblaws, Loblaws banner stores, Sobeys, Whole Foods and key natural accounts. This also represents a 181% increase from last year's Q2 report which had revenue of $166,052. Komo reported a gross profit margin of 39% in Q1 of 2023.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Doubles Retail Distribution to 840 Stores

Komo Doubles Retail Distribution to 840 Stores

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) (the "Company", "Komo"), a premium plant‐based food company, reports significant growth in the number of retail stores carrying Komo products with an increase of over 100% in 3 months.

Komo Plant Based Foods Inc., a fast-growing plant-based food products manufacturer, announces a 100% increase in retail distribution since November of 2022, now available in 840 grocery retail locations across Canada. This impressive growth includes Loblaw's and Loblaws' banner stores and the addition of 50 new retail stores in January 2023, including Georgia Main Group (IGA West and Fresh St. Market), Sobey's West, Safeway and Freson Brothers locations in western Canada, and key natural accounts such as Boites à Grain in Quebec.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Reports Q1 Financial Results

Komo Reports Q1 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the "Company", "Komo"), a premium plant‐based food company, reports financial results for the quarterly period ended October 31, 2022.

FINANCIAL RESULTS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Reports Fiscal Year 2022 Financial Results

Komo Reports Fiscal Year 2022 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ("Komo"), a premium plant-based food company, today reports financial results for the year ended July 31, 2022.

"We began our fiscal year as a new brand with a mission to make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. Thanks to the strength of our team and the love of Komo products, we were successful in achieving sales growth of 935 percent over last year," says Komo founder and CEO William White. "The consistently strong retail sales of our products have allowed us to demonstrate to large retail chains that our products sell well and have repeat customers. We recently completed a national listing with Loblaws and we are in discussions with several other large national chains. As a result, we are anticipating continued significant revenue increases in 2023."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×